Cargando…
Ibrutinib response in a patient with refractory mixed essential cryoglobulinemia
Autores principales: | Jamali, Haya, Wu, David, Soma, Lorinda, Linenberger, Michael, Wener, Mark H., Silberstein, Lev |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188461/ https://www.ncbi.nlm.nih.gov/pubmed/37206249 http://dx.doi.org/10.1002/jha2.686 |
Ejemplares similares
-
Scedosporium apiospermum brain abscesses in a patient receiving ibrutinib and venetoclax
por: Figueroa, Rocio, et al.
Publicado: (2020) -
Behçet's disease‐like clinical manifestations of chronic lymphocytic leukemia during good response to ibrutinib
por: Obama, Kosuke, et al.
Publicado: (2023) -
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
por: Richardson, Paul G., et al.
Publicado: (2018) -
Essential Type II Mixed Cryoglobulinemia Causing Pyoderma Gangrenosum–Like Ulcers
por: Namazi, M. R., et al.
Publicado: (2008) -
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials
por: Jones, Jeffrey, et al.
Publicado: (2018)